

Judith D Goldberg Scd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8980429/publications.pdf>

Version: 2024-02-01

61
papers

1,790
citations

448610

19
h-index

312153

41
g-index

72
all docs

72
docs citations

72
times ranked

3263
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized phase 3 trial of interferon- β vs hydroxyurea in polycythemia vera and essential thrombocythemia. <i>Blood</i> , 2022, 139, 2931-2941.	0.6	45
2	Elevated Levels of Urinary Biomarkers TIMP-2 and IGFBP-7 Predict Acute Kidney Injury in Neonates after Congenital Heart Surgery. <i>Journal of Pediatric Intensive Care</i> , 2022, 11, 153-158.	0.4	2
3	Adherence to guidelines at the patient and hospital levels is associated with improved overall survival in patients with gastric cancer. <i>Journal of Surgical Oncology</i> , 2022, 126, 479-489.	0.8	9
4	Examination of speakership gender disparity at an international oncology conference.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11002-11002.	0.8	2
5	Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's. <i>Contemporary Clinical Trials</i> , 2021, 107, 106488.	0.8	7
6	A Prospective Trial to Compare Deep Inspiratory Breath Hold With Prone Breast Irradiation. <i>Practical Radiation Oncology</i> , 2020, 10, 330-338.	1.1	5
7	Value of metalloproteinases in predicting COPD in heavy urban smokers. <i>Respiratory Research</i> , 2020, 21, 228.	1.4	5
8	Comparison of Clinical Measures Among Interstitial Lung Disease (ILD) Patients with Usual Interstitial Pneumonia (UIP) Patterns on High-Resolution Computed Tomography. <i>Lung</i> , 2020, 198, 811-819.	1.4	2
9	Pharmacodynamics of natalizumab extended interval dosing in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	22
10	A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 372-372.	0.8	3
11	Progression free survival (PFS) in Asian vs non-Asian patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) receiving osimertinib.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21679-e21679.	0.8	0
12	Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients. , 2019, 7, 177.		32
13	Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. <i>Neurology</i> , 2019, 93, e1452-e1462.	1.5	104
14	Plasma Zonulin Levels in Childhood Nephrotic Syndrome. <i>Frontiers in Pediatrics</i> , 2019, 7, 197.	0.9	12
15	ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM). <i>Neuro-Oncology</i> , 2019, 21, vi9-vi10.	0.6	3
16	Focal Irradiation and Systemic TGF β 2 Blockade in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2493-2504.	3.2	201
17	Delivery of adjuvant chemotherapy among stage III colon cancer patients at a public versus private hospital in New York City. <i>Cancer Causes and Control</i> , 2018, 29, 253-260.	0.8	1
18	Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 57-67.	1.1	15

#	ARTICLE	IF	CITATIONS
19	Serum albumin at 1 year predicts long-term renal outcome in lupus nephritis. <i>Lupus Science and Medicine</i> , 2018, 5, e000271.	1.1	8
20	Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms. <i>Blood Advances</i> , 2018, 2, 3572-3580.	2.5	51
21	071â€¦Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch^{Â®} prescribing program. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A29.2-A29.	0.9	4
22	Results of a phase II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer. <i>Oncolmmunology</i> , 2017, 6, e1274479.	2.1	10
23	A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). <i>Leukemia Research</i> , 2017, 53, 13-19.	0.4	35
24	Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 144, 279-284.	0.6	29
25	Multifocal Invasive Ductal Cancer: Distinguishing Independent Tumor Foci From Multiple Satellites. <i>International Journal of Surgical Pathology</i> , 2017, 25, 298-303.	0.4	6
26	Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1124-TPS1124.	0.8	3
27	Likelihood ratio and score tests to test the non-inferiority (or equivalence) of the odds ratio in a crossover study with binary outcomes. <i>Statistics in Medicine</i> , 2016, 35, 3471-3481.	0.8	5
28	Inflammatory cytokines and non-small cell lung cancer in a CT-scan screening cohort: Background review of the literature. <i>Cancer Biomarkers</i> , 2016, 16, 219-233.	0.8	22
29	Prospective Randomized Trial of Prone Accelerated Intensity Modulated Breast Radiation Therapy With a Daily Versus Weekly Boost to the Tumor Bed. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 571-578.	0.4	19
30	Preplanning prediction of the left anterior descending artery maximum dose based on patient, dosimetric, and treatment planning parameters. <i>Advances in Radiation Oncology</i> , 2016, 1, 373-381.	0.6	9
31	Cell cycle features of <i>C. elegans</i> germline stem/progenitor cells vary temporally and spatially. <i>Developmental Biology</i> , 2016, 409, 261-271.	0.9	27
32	Quality of Life in Women Undergoing Breast Irradiation in a Randomized, Controlled ClinicalÂTrial Evaluating Different Tumor Bed Boost Fractionations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 579-589.	0.4	5
33	Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy. <i>Clinical Breast Cancer</i> , 2016, 16, 113-122.e1.	1.1	49
34	Methylation profiling of locally advanced rectal cancer (LARC): Exploration of potential predictive markers for neoadjuvant chemoradiation (NACR).. <i>Journal of Clinical Oncology</i> , 2016, 34, 614-614.	0.8	0
35	Surveillance Epidemiology and End Results Analysis Demonstrates Improvement in Overall Survival for Cervical Cancer Patients Treated in the Era of Concurrent Chemoradiotherapy. <i>Frontiers in Oncology</i> , 2015, 5, 81.	1.3	11
36	Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. <i>Blood</i> , 2015, 126, 972-982.	0.6	58

#	ARTICLE	IF	CITATIONS
37	Phase I dose escalation study of lestaurtinib in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2015, 56, 2543-2551.	0.6	29
38	Clinical Trial Evidence of the Antitumor Activity of Topical Imiquimod for Breast Cancer Skin Metastases. <i>Journal of Clinical Oncology</i> , 2014, 32, 3204-3205.	0.8	8
39	Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. <i>Neuro-Oncology</i> , 2014, 16, 1408-1416.	0.6	175
40	Prone Breast Intensity Modulated Radiation Therapy: 5-Year Results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 899-906.	0.4	41
41	MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. <i>Blood</i> , 2014, 124, 1183-1191.	0.6	135
42	A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5564-5564.	0.8	2
43	Concurrent adjuvant systemic therapy and accelerated radiotherapy in triple-negative breast cancer: A feasibility trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS1147-TPS1147.	0.8	0
44	Novel combination of toll-like receptor (TLR)-7 agonist imiquimod and local radiotherapy in the treatment of breast cancer chest wall recurrences or skin metastases.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS3122-TPS3122.	0.8	1
45	Hyperactivated mTOR and JAK2/STAT3 pathways: Crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11106-11106.	0.8	0
46	Prone vs Supine Positioning for Breast Cancer Radiotherapy. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 861.	3.8	138
47	Prone Hypofractionated Whole-Breast Radiotherapy Without a Boost to the Tumor Bed: Comparable Toxicity of IMRT Versus a 3D Conformal Technique. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e415-e423.	0.4	40
48	Prospective Assessment of Optimal Individual Position (Prone Versus Supine) for Breast Radiotherapy: Volumetric and Dosimetric Correlations in 100 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 902-909.	0.4	120
49	Pathologic response rate in HER2-positive locally advanced breast cancers treated with neoadjuvant trastuzumab and concurrent paclitaxel/radiotherapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11064-e11064.	0.8	0
50	Meta-analysis to Assess the Appropriate Endpoint for Slow Pathway Ablation of Atrioventricular Nodal Reentrant Tachycardia. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2011, 34, 269-277.	0.5	27
51	Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis. <i>Blood</i> , 2011, 118, 1750-1750.	0.6	2
52	Prolonged Low Dose Therapy with a Pan-Deacetylase Inhibitor, Panobinostat (LBH589), in Patients with Myelofibrosis. <i>Blood</i> , 2011, 118, 794-794.	0.6	9
53	A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).. <i>Blood</i> , 2009, 114, 308-308.	0.6	17
54	A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC).. <i>Blood</i> , 2009, 114, 754-754.	0.6	19

#	ARTICLE	IF	CITATIONS
55	Thrombopoietin Receptor (MPL) Genotype Modifies the Myeloproliferative Phenotype in a JAK2 V617F Transgenic Mouse Model of Polycythemia Vera.. Blood, 2009, 114, 964-964.	0.6	0
56	Abnormal P-Selectin Localization During Megakaryocyte Development Determines Thrombosis in the Gata1 ^{low} Model of Myelofibrosis.. Blood, 2009, 114, 1907-1907.	0.6	0
57	Correlation of Novel Molecular Markers in Patients with Myeloproliferative Neoplasms.. Blood, 2009, 114, 4968-4968.	0.6	2
58	Phase III Trial of Prone Accelerated Intensity Modulated Radiation Therapy to the Breast to Optimally Spare Normal Tissue. Journal of Clinical Oncology, 2007, 25, 2236-2242.	0.8	154
59	The effects of outcome misclassification and measurement error on the design and analysis of therapeutic equivalence trials. Statistics in Medicine, 2001, 20, 2065-2078.	0.8	29
60	Increased prevalence of polycythemia vera in parents of patients on polycythemia vera study group protocols. American Journal of Hematology, 1984, 16, 367-373.	2.0	19
61	Statistics in Medicine.. Journal of the American Statistical Association, 1977, 72, 923.	1.8	0